预约演示
更新于：2025-05-19
Pazufloxacin Mesilate
甲磺酸帕珠沙星
更新于：2025-05-19
概要
基本信息
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (2002-04-11), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H19FN2O7S |
InChIKeyUDHGFPATQWQARM-FJXQXJEOSA-N |
CAS号163680-77-1 |
关联
10
项与 甲磺酸帕珠沙星 相关的临床试验NCT03696342
Clinical Study of the Efficacy of the Ophthalmic Solution of Pazufloxacin 0.6% (PRO-157) for the Treatment of Acute Bacterial Conjunctivitis, Compared to the Ophthalmic Solution of Gatifloxacin 0.3%.
NCT03675841
A Phase I，Pazufloxacin Mesilate Ear Drops in Patients With Chronic Suppurative Otitis Media
NCT02592096
A Single Dose Phase I Clinical Study of Pazufloxacin Mesilate Ear Drops for the Patients With Otitis Media
100 项与 甲磺酸帕珠沙星 相关的临床结果
登录后查看更多信息
100 项与 甲磺酸帕珠沙星 相关的转化医学
登录后查看更多信息
100 项与 甲磺酸帕珠沙星 相关的专利（医药）
登录后查看更多信息
675
项与 甲磺酸帕珠沙星 相关的文献（医药）2025-08-01SEPARATION AND PURIFICATION TECHNOLOGY
Environmentally friendly synthesis of quasi-MIL-100(Fe) with modulation defects for efficient photo-Fenton degradation of ciprofloxacin
作者: Ma, Xianyun ; Zhang, Sanbing ; Liu, Yajia ; Miao, Chang-qing ; Zhu, Bowen ; Wang, Min ; Li, Zuopeng
Defect engineering is a promising approach for constructing highly efficient catalytic activity based on metal-organic frameworks (MOFs).In this study, a defective MOFs, referred to as quasi-MIL-100(Fe), was synthesized by moderate synthesis method and then careful thermal treatment at an atm. ranging from 150 to 450°C, linking crystalline materials and the associated metal oxides.MIL-100(Fe) heat-treated at 250°C (referred to as M-250) partially breaks coordination bonds, resulting in a crystalline-to-amorphous transformation, increased porosity, and elimination of ligands.Compared to pristine MIL-100(Fe), M-250 possessed more reactive sites and exhibited the highest photo-Fenton degradation of ciprofloxacin with 95.6% removal efficiency in 90 min, despite the unfavorable photo properties for photo-Fenton performance due to the destruction of the crystal structure.Addnl., d. functional theory (DFT) calculations, combined with free radical quenching and mass spectrometry anal., elucidated the catalytic mechanism.These findings highlight the significant potential of quasi-MOFs for applications in the photo-Fenton reaction.
2025-04-21JOURNAL OF DRUG TARGETING
Artificial intelligence-based molecular property prediction of photosensitising effects of drugs
Article
作者: Hofmann, Amun G. ; Agibetov, Asan ; Weber, Benedikt ; Ibbotson, Sally
Drug-induced photosensitivity is a potential adverse event of many drugs and chemicals used across a wide range of specialties in clinical medicine. In the present study, we investigated the feasibility of predicting the photosensitising effects of drugs and chemical compounds via state-of-the-art artificial intelligence-based workflows. A dataset of 2200 drugs was used to train three distinct models (logistic regression, XGBoost and a deep learning model (Chemprop)) to predict photosensitising attributes. Labels were obtained from a list of previously published photosensitisers by string matching and manual validation. External evaluation of the different models was performed using the tox21 dataset. ROC-AUC ranged between 0.8939 (Chemprop) and 0.9525 (XGBoost) during training, while in the test partition it ranged between 0.7785 (Chemprop) and 0.7927 (XGBoost). Analysis of the top 200 compounds of each model resulted in 55 overlapping molecules in the external validation set. Prediction scores in fluoroquinolones within this subset corresponded well with culprit substructures such as fluorinated aryl halides suspected of mediating photosensitising effects. All three models appeared capable of predicting photosensitising effects of chemical compounds. However, compared to the simpler model, the complex models appeared to be more confident in their predictions as exhibited by their distribution of prediction scores.
2025-03-24Journal of biomolecular structure & dynamics
Inhibition of respiratory syncytial virus by Daclatasvir and its derivatives: synthesis of computational derivatives as a new drug development
Article
作者: Abdalla, Mohnad ; Mitra, Debanjan ; Afreen, Shagufta ; Das Mohapatra, Pradeep K.
The most common cause of respiratory tract illness in newborns and young children is the respiratory syncytial virus (RSV). There is no approved vaccination or specific antiviral medication for RSV infections. Here, an attempt has been made to explore the potential of currently marketed drugs as well as their probable derivatives to improve the possibility of developing stronger medications against RSV. From the 100 synthetic drug compounds library, the best drug molecule was identified through drug-likeness properties, toxicity, molecular docking and molecular dynamics simulations. Molecular Mechanics Generalized Born Surface Area (MM-GBSA) was also a method that was applied in this study. Daclatasvir showed the highest binding energy and appeared as the best drug to inhibit matrix protein and a fusion protein of RSV. Based on Daclatasvir, 40 computational derivatives were made. D28, D34 and D40 showed far better results than the actual drug. Changes in lipophilicity character increase the binding energy of derivatives. Molecular dynamic simulations showed their non-deviated, non-fluctuated and stable complex formation with target proteins. The high number of amino acid contacts throughout the trajectory increases the stability and effectiveness of derivatives. The key to producing a novel medicine to eradicate RSV is provided by derivatives. Daclatasvir will be employed as a potential RSV inhibitor up until that point.
100 项与 甲磺酸帕珠沙星 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 感染 | 中国 | 2004-01-01 | |
| 细菌感染 | 日本 | 2002-04-11 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性化脓性中耳炎 | 临床1期 | 中国 | 2015-07-24 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 46 | (PRO-157) | 膚獵獵簾網積簾顧鏇遞 = 繭積醖選顧鑰餘廠蓋積 膚襯遞觸鏇築積遞壓製 (觸淵膚窪鬱艱選鑰鹹鹹, 願壓網廠膚艱憲簾夢夢 ~ 願構糧範衊鹹鏇鬱構糧) 更多 | - | 2021-08-24 | ||
(Zymar) | 膚獵獵簾網積簾顧鏇遞 = 蓋糧願構觸觸窪繭願廠 膚襯遞觸鏇築積遞壓製 (觸淵膚窪鬱艱選鑰鹹鹹, 繭壓窪獵夢網鏇膚願積 ~ 窪鑰憲獵壓鬱鬱憲膚鑰) 更多 | ||||||
临床2期 | 150 | (PRO-157 BID (2 Times Per Day)) | 夢鏇遞鏇襯齋餘簾選繭 = 構鬱積觸艱鏇築鬱膚簾 蓋醖繭選構繭觸憲餘積 (網網糧廠襯願獵壓憲選, 餘鹹餘廠齋遞蓋鬱繭壓 ~ 壓鬱選選鹹糧糧夢鑰鏇) 更多 | - | 2019-02-15 | ||
(PRO-157 TID (3 Times Per Day)) | 夢鏇遞鏇襯齋餘簾選繭 = 簾壓範鏇廠鹹積製憲鬱 蓋醖繭選構繭觸憲餘積 (網網糧廠襯願獵壓憲選, 膚築淵夢壓衊顧願醖艱 ~ 製糧顧廠鏇齋繭窪鑰蓋) 更多 | ||||||
临床2期 | 300 | Pazufloxacin 0.09% BID | 廠淵築構窪夢積構繭鹹(襯襯構淵鹽顧鏇窪糧窪) = 窪醖顧窪壓築構鹽窪餘 襯壓蓋顧蓋壓鹽顧糧築 (鏇鬱觸餘鏇築艱壓願獵 ) | 积极 | 2017-05-07 | ||
Pazufloxacin 0.09% TID | 廠淵築構窪夢積構繭鹹(襯襯構淵鹽顧鏇窪糧窪) = 積蓋蓋網願憲夢蓋鑰選 襯壓蓋顧蓋壓鹽顧糧築 (鏇鬱觸餘鏇築艱壓願獵 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用